<DOC>
	<DOCNO>NCT01995383</DOCNO>
	<brief_summary>This single-center , randomize , placebo-controlled , double-blind study ass safety , pharmacokinetics pharmacodynamics RO6836191 healthy male volunteer two part . Part 1 ass safety oral single ascending dos RO6836191 compare placebo fast volunteer . In Part 2 , participant give two single oral dos RO6836191 placebo low normal-salt diet condition . A subset participant subsequently receive single IV dose RO6836191 analysis .</brief_summary>
	<brief_title>A Single Ascending Dose Study Investigating Safety , Pharmacokinetics Pharmacodynamics RO6836191 Healthy Male Volunteers .</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Healthy male volunteer , age 18 45 year old . No active chronic disease follow detailed medical surgical history complete physical examination . A BMI 18 30 kg/m2 inclusive . Use highly effective form birth control duration study 90 day last dose . Any clinically relevant current history condition illness . Clinically significant symptom infection within 5 day first dose day history recurrent infection . Any suspicion history alcohol abuse and/or consumption drug abuse . Smokers unable unwilling restrict 5 cigarette daily study smoke stay clinic . Any cardiac abnormality . Blood donation 450 mL within three month prior screen . Participation investigational drug device study within 3 month prior dose . Corticosteroid use within 3 month prior dose .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>